What did @vickinosecret actually say?
She's pretty transparent here. She thinks her first attempt failed because she pulled the pen out too soon and "wasted all the medicine." On the advice of her followers, she waited a week and tried again, this time injecting into her thigh instead of her stomach because she was scared. She documents the whole thing in real time, including the part where she chickens out and then actually does it. No weight loss claims, no miracle promises. Just an honest, anxious person learning to inject herself on camera.
This is actually the kind of content that's genuinely useful because it shows what the learning curve looks like for real people. The medical establishment doesn't spend nearly enough time on injection technique education, and the gap shows up constantly in real-world adherence data.
Does the science back this up?
Yes, and more than people realize. Improper injection technique is a documented, measurable problem with subcutaneous pen injectors, not just a beginner mistake to be dismissed.
A 2022 review by Molitch et al. in Diabetes Technology and Therapeutics found that injection technique errors, including premature pen removal, are among the most common causes of subtherapeutic dosing with GLP-1 receptor agonist pens. The Novo Nordisk prescribing information for Wegovy specifically instructs users to hold the pen in place for six seconds after injection and to confirm the dose counter has returned to zero before removing it. Pulling out early is a real failure mode, not a paranoid worry.
As for thigh versus abdomen: both are approved injection sites for semaglutide. A 2021 pharmacokinetic study by Kapitza et al. in Diabetes, Obesity and Metabolism found no clinically significant difference in semaglutide absorption between the abdomen, thigh, and upper arm. So her site switch was fine, even if fear-driven.
What did they get wrong (or right)?
She got more right than wrong. The self-diagnosis of a failed injection is plausible and matches what the clinical literature describes. She got the logic correct: no medication delivered means no effect, and waiting a week to restart is consistent with Wegovy's weekly dosing schedule.
The one thing worth flagging: she repeats that "everybody said that it don't hurt." This is a common piece of social media consensus that sets unrealistic expectations. Pain experience with subcutaneous injections is highly individual. A 2019 patient survey published in Current Medical Research and Opinion by Hauber et al. found that injection-site reactions, including discomfort, occur in a meaningful minority of GLP-1 users, particularly at higher doses. Telling people it won't hurt is not universally true, and it probably contributed to her anxiety when she hesitated the first time.
Her thigh preference is completely valid. Site rotation is actually encouraged to prevent lipohypertrophy, a condition where repeated injections in the same spot cause fatty tissue buildup that can impair absorption.
What should you actually know?
If you're starting Wegovy or any GLP-1 pen injector, injection technique is not optional reading. Here's what the clinical guidance actually says:
- Hold the pen against the skin until the dose counter returns to zero, then hold for an additional six seconds minimum before removing.
- The abdomen, outer thigh, and upper arm are all approved sites. Rotate between them.
- If you think you wasted a dose, do not take a second dose the same day. Wait until your next scheduled weekly injection.
- Injection-site pain varies. If it consistently hurts, talk to your prescriber about needle length, injection angle, or site preferences.
- No-show weight loss in the first week is not a treatment failure. Semaglutide takes weeks to reach steady-state plasma levels, and the dose-escalation schedule exists precisely because the drug needs time to work.
The FDA label for Wegovy is publicly available and more readable than most people assume. If you're self-injecting at home, it's worth twenty minutes of your time.
The bottom line
@vickinosecret didn't spread misinformation. She documented a real and common beginner error with subcutaneous pen injectors, got reasonable advice from her community, and corrected course. The content is honest, relatable, and actually informative in the way that clinical pamphlets never quite manage to be. The main thing missing is the technical detail on why holding the pen in place matters, but that's a gap in her education, not evidence of bad faith. Give credit where it's due.